Home / Nervous system / Cabergoline
ATC N04BC06 · Anti-Parkinson Drugs
Cabergoline shortage
As of 31 Oct 2026, Cabergoline has a reported shortage in 2 of the 5 countries we track (Germany, Spain), covering 5 products.
Countries2/5
Products5packs or presentations
Short since1 Jun 20265 months ago
Earliest return19 Nov 2026company estimate
No return date0products
Main reasonActive ingredient shortage
Timeline
GermanySpain
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Affected products
| Country | Product | Holder | Since | Expected back | Reason |
|---|---|---|---|---|---|
| DE | Cabaseril 1 mg | Pfizer Pharma GmbH | 1 Jun 2026 | 15 Dec 2026 | Active ingredient shortage Probleme beim Wirkstoffhersteller |
| DE | Cabaseril 1 mg | Pfizer Pharma GmbH | 1 Jun 2026 | 15 Dec 2026 | Active ingredient shortage Probleme beim Wirkstoffhersteller |
| DE | Cabaseril 2 mg | Pfizer Pharma GmbH | 1 Jun 2026 | 15 Dec 2026 | Active ingredient shortage Probleme beim Wirkstoffhersteller |
| DE | Cabaseril 2 mg | Pfizer Pharma GmbH | 1 Jun 2026 | 15 Dec 2026 | Active ingredient shortage Probleme beim Wirkstoffhersteller |
| ES | CABERGOLINA TEVA 1 mg COMPRIMIDOS EFG , 20 comprimidos | Teva Gmbh | 23 Aug 2026 | 19 Nov 2026 | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.